Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bexarotene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA known ✓ | P19793 | 20/20 | 1.00 |
| ▸ | RXRB known ✓ | P28702 | 7/20 | 1.00 |
| ▸ | RXRG known ✓ | P48443 | 7/20 | 1.00 |
| ▸ | RARB | P10826 | 6/20 | 1.00 |
| ▸ | RARG | P13631 | 5/20 | 1.00 |
| ▸ | RARA | P10276 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP26A1 | O43174 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bexarotene SCHEMBL29412584 | 1.00 | RXRA (1.00) | RXRARXRBRXRGRARBRARG | |
| Bexarotene SCHEMBL5322954 | 1.00 | RXRA (1.00) | RXRARXRBRXRGRARBRARG | |
| Bexarotene SCHEMBL4432606 | 0.99 | RXRA (0.97) | RXRARXRBRXRGRARBRARG | |
| Bexarotene SCHEMBL28672173 | 0.97 | RXRA (0.94) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL24055307 | 0.95 | RXRA (0.90) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL24055118 | 0.95 | RXRA (0.90) | RXRARXRBRXRGRARBRARG | |
| Bexarotene SCHEMBL2571575 | 0.93 | RXRA (0.87) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL16926899 | 0.91 | RXRA (0.84) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL6891228 | 0.91 | RXRA (0.84) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL19119460 | 0.90 | RXRA (0.81) | RXRARXRBRXRGRARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 43856 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026104588-A1 | UROLITHIN COMBINATION | AMAZENTIS SA (CH) | 2026-05-21 | — | — | WO | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| CN-122057026-A | Pharmaceutical composition for treating multiple myeloma and application thereof | 南京鼓楼医院 | 2026-05-19 | — | — | CN | claimed |
| US-20260132141-A1 | PROTEIN PHOSPHATASE 2A ACTIVATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-14 | — | — | US | claimed |
| EP-4741421-A1 | FAB-ARM EXCHANGE-PREVENTING FC VARIANTS FROM WHICH EFFECTOR FUNCTIONS ARE REMOVED | Korea University Research and Business Foundation (KR) | 2026-05-13 | — | — | EP | claimed |
| US-20260108476-A1 | 2,4 DNP and Prodrugs Thereof for Treatment of Cancer | MITOCHON PHARMACEUTICALS, INC. (US) | 2026-04-23 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-4727596-A2 | ANTIBODY-DRUG CONJUGATES AND LINKERS AND METHODS OF USE THEREOF | Ohio State Innovation Foundation (US) | 2026-04-22 | — | — | EP | claimed |
| EP-3515892-B1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2026-04-15 | — | — | EP | claimed |
| EP-0983992-A2 | Compounds having selectivity for retinoid x receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2000-03-08 | — | — | EP | claimed |
| US-6028088-A | USEFUL AS ANTIPROLIFERATIVE, ANTIINFLAMMATORY AND ANTIINFECTIVE AGENTS; FOR TREATMENT OF CERTAIN ENDOCRINE DISEASES INCLUDING DIABETES, CERTAIN MALIGNANT AND NON-MALIGNANT PROLIFERATIVE DISEASES INCLUDING PROSTATE CANCER | THE UNIVERSITY OF MISSISSIPPI (US) | 2000-02-22 | — | — | US | claimed |
| US-6025133-A | NUCLEIC ACID SEQUENCE INCLUDING A RNA POLYMERASE PROMOTER; FORMS A STEM-LOOP STRUCTURE IN THE ABSENCE OF TARGET SEQUENCE; FOR AMPLIFYING NUCLEIC ACID USING A TARGET NUCLEIC ACID SEQUENCE TO TRIGGER TRANSCRIPTION; DIAGNOSTIC TESTS | GEN-PROBE INCORPORATED (US) | 2000-02-15 | — | — | US | claimed |
| EP-0963199-A1 | TREATMENT OF DISEASE STATES WHICH RESULT FROM NEOPLASTIC CELL PROLIFERATION USING PPAR-GAMMA ACTIVATORS AND COMPOSITIONS USEFUL THEREFOR | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1999-12-15 | — | — | EP | claimed |
| WO-1999058155-A1 | FORMULATIONS USEFUL FOR MODULATING EXPRESSION OF EXOGENOUS GENES IN MAMMALIAN SYSTEMS, AND PRODUCTS RELATED THERETO | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1999-11-18 | — | — | WO | claimed |
| WO-1998029120-A1 | TREATMENT OF LIPOSARCOMAS USING A COMBINATION OF THIAZOLIDINEDIONES AND RETINOID X RECEPTOR SELECTIVE AGONISTS | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1998-07-09 | — | — | WO | claimed |
| WO-1998029113-A1 | TREATMENT OF DISEASE STATES WHICH RESULT FROM NEOPLASTIC CELL PROLIFERATION USING PPAR-GAMMA ACTIVATORS AND COMPOSITIONS USEFUL THEREFOR | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1998-07-09 | — | — | WO | claimed |
| EP-0637297-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 1995-02-08 | — | — | EP | claimed |
| WO-1993021146-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1993-10-28 | — | — | WO | claimed |
| EP-0254122-B1 | METHOD FOR INCREASING THE HIT PROBABILITY OF MULTIPLE-TUBE MACHINE GUNS | Mauser-Werke Oberndorf GmbH (DE) | 1990-07-04 | — | — | EP | claimed |